Stockreport

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

Affimed N.V.  (AFMD) 
Last affimed n.v. earnings: 11/19 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: affimed.com/investor-relations.php
PDF HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their i [Read more]